Alectinib, an ALK inhibitor, Has a DFS Advantage in Early NSCLC.

Published Date: 24 Oct 2023

The ALINA trial's preliminary results indicate that in resected stage IB-IIIA NSCLC, adjuvant alectinib treatment improved overall survival compared with chemotherapy. Will the overall survival outcome match the early DFS results?

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot